相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
Yuankai Shi et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Youjin Kim et al.
CANCER RESEARCH AND TREATMENT (2019)
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
Rui-Mei Feng et al.
CANCER COMMUNICATIONS (2019)
Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry
Xiaoyun Liu et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2019)
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib
Karthick Vishwanathan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors
Weiwei Han et al.
CHEMISTRY & BIODIVERSITY (2017)
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2017)
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
S. S. Ramalingam et al.
ANNALS OF ONCOLOGY (2016)
Recent progress on third generation covalent EGFR inhibitors
Hengmiao Cheng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes
Vaishali Dixit et al.
DRUG METABOLISM AND DISPOSITION (2016)
Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor
Paul A. Dickinson et al.
DRUG METABOLISM AND DISPOSITION (2016)
The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers
Varun Garg et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Simulation of Clinical Drug-Drug Interactions from Hepatocyte CYP3A4 Induction Data and Its Potential Utility in Trial Designs
Yang Xu et al.
DRUG METABOLISM AND DISPOSITION (2011)
Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR
Antonia H. Tolson et al.
ADVANCED DRUG DELIVERY REVIEWS (2010)
Evaluation of models for predicting drug-drug interactions due to induction
Odette A. Fahmi et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction
Magang Shou et al.
DRUG METABOLISM AND DISPOSITION (2008)
New molecularly targeted therapies for lung cancer
Sophie Sun et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
New targets for non-small-cell lung cancer therapy
Manrique Alvarez et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Bitter pills and puffed trials - Reply
V Barbour et al.
PLOS MEDICINE (2005)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
分享论文
